Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 May 30;14(5):2536-2538.
doi: 10.21037/tcr-2025-295. Epub 2025 May 13.

Does circulating DNA tumor fraction add value to prostate-specific antigen in metastatic castration-resistant prostate cancer?

Cora N Sternberg  1   2 , Maha Hussain  3
Affiliations
Editorial

Does circulating DNA tumor fraction add value to prostate-specific antigen in metastatic castration-resistant prostate cancer?

Cora N Sternberg et al. Transl Cancer Res. .
No abstract available

Keywords: Circulating tumor DNA (ctDNA); metastatic castration-resistant prostate cancer (mCRPC); tumor fraction (TF).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://tcr.amegroups.com/article/view/10.21037/tcr-2025-295/coif). C.N.S. has received funds from Astellas Pharma, AstraZeneca, Bayer, Bristol-Myers Squibb/Medarex, Foundation Medicine, Genzyme, Gilead, Merck, MSD, Pfizer, Janssen, Roche, Medscape, UroToday, and Tolmar. M.H. has received funds from Bayer, Convergent, Astra Zeneca, MJH, RTP, PER, BMS and is a trustee, member of Board of Prostate Cancer, UK and member of Steering Committee, MOVEMBER Global Collaborative Program in Disease Progression. The authors have no other conflicts of interest to declare.

Comment on

References

    1. Sweeney CJ, Petry R, Xu C, et al. Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res 2024;30:4115-22. 10.1158/1078-0432.CCR-24-1096 - DOI - PMC - PubMed
    1. Powles T, Yuen KC, Gillessen S, et al. Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial. Nat Med 2022;28:144-53. 10.1038/s41591-021-01600-6 - DOI - PMC - PubMed
    1. Armstrong AJ, Luo J, Nanus DM, et al. Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer. JCO Precis Oncol 2020;4:PO.20.00200. - PMC - PubMed
    1. Fonseca NM, Maurice-Dror C, Herberts C, et al. Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer. Nat Commun 2024;15:1828. 10.1038/s41467-024-45475-w - DOI - PMC - PubMed
    1. Woodhouse R, Li M, Hughes J, et al. Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin. PLoS One 2020;15:e0237802. 10.1371/journal.pone.0237802 - DOI - PMC - PubMed